Testing a new drug combination for hard-to-treat blood cancer

This clinical trial is testing a combination of two medications — belantamab mafodotin and venetoclax — to treat multiple myeloma that has returned or become resistant to prior treatments. The study will also explore whether adding a third medication, dexamethasone, improves results. Researchers want to learn whether this medication combination is safe and how well it works for patients with a specific genetic marker in their cancer cells.

Multiple myeloma that returns or stops responding to standard treatments is very difficult to manage, and patients need new options. This medication combination targets the disease in a different way, and early research suggests it might help patients whose cancers have this specific genetic change.